{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=11", "query": { "intervention": "Placebo Intravenous", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 2346, "total_pages": 235, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T22:35:14.233Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07219459", "title": "Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Unresectable or Metastatic Hepatocellular Carcinoma", "Child-Pugh A Hepatocellular Carcinoma", "Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound" ], "interventions": [ { "name": "Visugromab RDE (recommended dose for expansion)", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Placebo Saline Infusion", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "CatalYm GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 104, "start_date": "2026-03-19", "completion_date": "2031-09", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-12T22:35:14.233Z", "location_count": 6, "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 3 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07219459" }, { "nct_id": "NCT07203079", "title": "Oral Versus Intravenous Acetaminophen in Lumbar Spine Surgery", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Postoperative Pain" ], "interventions": [ { "name": "Acetaminophen Oral Tablet", "type": "DRUG" }, { "name": "placebo oral tablet", "type": "DRUG" }, { "name": "Acetaminophen infusion", "type": "DRUG" }, { "name": "Placebo infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2026-01", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-10-12T22:35:14.233Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07203079" }, { "nct_id": "NCT02125461", "title": "A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "MEDI4736", "type": "DRUG" }, { "name": "PLACEBO", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 713, "start_date": "2014-05-07", "completion_date": "2023-08-24", "has_results": true, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-10-12T22:35:14.233Z", "location_count": 60, "location_summary": "Chandler, Arizona • Goodyear, Arizona • Jonesboro, Arkansas + 53 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02125461" }, { "nct_id": "NCT03016325", "title": "Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "HNO Donor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2017-01-13", "completion_date": "2019-11-12", "has_results": true, "last_update_posted_date": "2021-01-06", "last_synced_at": "2026-10-12T22:35:14.233Z", "location_count": 24, "location_summary": "Tucson, Arizona • Gainesville, Florida • Tampa, Florida + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03016325" }, { "nct_id": "NCT01231620", "title": "A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "Zanamivir", "type": "DRUG" }, { "name": "Placebo to match zanamivir", "type": "DRUG" }, { "name": "Oseltamivir", "type": "DRUG" }, { "name": "Placebo to match oseltamivir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 626, "start_date": "2011-01-15", "completion_date": "2015-03-18", "has_results": true, "last_update_posted_date": "2018-10-15", "last_synced_at": "2026-10-12T22:35:14.233Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01231620" }, { "nct_id": "NCT01855880", "title": "Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Moderate to Severe Chronic Plaque Psoriasis" ], "interventions": [ { "name": "AbGn-168H", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AbGenomics B.V Taiwan Branch", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 54, "start_date": "2013-05", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2015-05-08", "last_synced_at": "2026-10-12T22:35:14.233Z", "location_count": 15, "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Boynton Beach, Florida + 11 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Ocala", "state": "Florida" }, { "city": "Orange", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01855880" }, { "nct_id": "NCT04389840", "title": "Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Coronavirus Disease 2019 (COVID-19)", "Acute Lung Injury", "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)" ], "interventions": [ { "name": "Dociparstat sodium", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 27, "start_date": "2020-07-08", "completion_date": "2021-05-20", "has_results": true, "last_update_posted_date": "2022-08-30", "last_synced_at": "2026-10-12T22:35:14.233Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Loxahatchee Groves, Florida • Augusta, Georgia + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Loxahatchee Groves", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04389840" }, { "nct_id": "NCT02479789", "title": "Efficacy of Intravenous Lidocaine in the Operative Management of Thyroid Surgery With Intraoperative Nerve Monitoring", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Thyroidectomy", "Nerve Monitoring" ], "interventions": [ { "name": "Lidocaine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bronx-Lebanon Hospital Center Health Care System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 66, "start_date": "2015-06", "completion_date": "2018-07", "has_results": false, "last_update_posted_date": "2018-02-22", "last_synced_at": "2026-10-12T22:35:14.233Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02479789" }, { "nct_id": "NCT03820986", "title": "Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Placebo for lenvatinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 674, "start_date": "2019-03-12", "completion_date": "2024-11-01", "has_results": true, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-10-12T22:35:14.233Z", "location_count": 17, "location_summary": "Los Angeles, California • San Francisco, California • Santa Monica, California + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03820986" }, { "nct_id": "NCT03867383", "title": "Calcium Chloride for Prevention of Uterine Atony During Cesarean", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Uterine Atony", "Uterine Atony With Hemorrhage", "Cesarean Section Complications" ], "interventions": [ { "name": "Calcium Chloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 40, "start_date": "2019-03-15", "completion_date": "2021-08-15", "has_results": true, "last_update_posted_date": "2022-04-28", "last_synced_at": "2026-10-12T22:35:14.233Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03867383" } ] }